【摘要】 为了评价沙培林(OK-432)联合化疗治疗癌性胸腔积液的疗效,对2000年3月~2002年7月收治的42例患者随机分为两组,治疗组胸腔内给予化疗药物和OK-432,每周1次;对照组仅用腔内化疗,药物同治疗组。结果示,治疗组CR2例,PR16例,有效率为85·7%(18/21);对照组CR1例,PR11例,有效率57·2%(12/21)。二者差异有统计学意义,Uc=2.011,P<0·05。初步研究结果提示,OK-432与化疗联用治疗癌性胸腔积液的疗效明显优于单用腔内化疗,且这种方法对患者损伤小,简便易操作,毒副反应轻微。更多还原

【Abstract】 The objective of this study was to evaluate the efficacy of OK-432 and chemotherapy for the patients with malignant pleural effusion. Forty-two patients with malignant pleural effusion were dividied into two groups: in the treatment group, 21 patients underwent introplerual therapy with Etopside and Cisplantin and intropleural injection of OK-432 5 KE every week; in the control group,21 patients only introplerual therapy with chemotherapy every week. The response rate of treatment group was 85.7%(18/21), 2 patients were CR and 16 patients PR; the response rate of the control was 57.2%(12/21),1 patient was CR and 11 patients PR.The significant difference was observed between two groups, Uc=2.011, P<0.05. In conclusion, the combined therapy with OK-432 and chemotherapy is superior to single drug of chemotherapy in patients with malignant pleural effusion. This therapy has an advantage in less injury, draining completely and smaller side effect.更多还原